The Washington University trial comes as part of a larger platform study which hopes to understand if Alzheimer's disease can ...

Novo Nordisk CEO Lars Fruergaard Jørgensen weighs in the company's latest obesity drug offering, including its new oral weight loss candidate.

We recently published a list of Jim Cramer’s Thoughts on These 7 Stocks. In this article, we are going to take a look at ...

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

Weight-loss drugs are transforming health care and Wall Street, but exciting prospects don’t necessarily mean a company is a good investment.

**NM signifies a non meaningful value. A dash signifies the data is not available.

Cardinal Health had $210 billion in pharmaceutical and specialty drugs sales in fiscal 2024, up 11% year-over-year, helped in large part by GLP-1 sales. In Q4, segment sales rose 13% to $55 billion, ...

One of the most important launches for Novartis in recent years is off with a bang. | One of the most important launches for ...

It’s a problem that has plagued European governments for decades, from the credit-crunch bank bailouts of 2008 to more recent ...